Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019;15(10):2295-2314.
doi: 10.1080/21645515.2019.1658503. Epub 2019 Oct 7.

A review of Dengvaxia®: development to deployment

Stephen J Thomas  1 , In-Kyu Yoon  2
Affiliations
Review

A review of Dengvaxia®: development to deployment

Stephen J Thomas et al. Hum Vaccin Immunother. 2019.

Abstract

Dengue is the world's most prevalent and important arboviral disease. More than 50% of the world's population lives at daily risk of infection and it is estimated more than 95 million people a year seek medical care following infection. Severe disease can manifest as plasma leakage and potential for clinically significant hemorrhage, shock, and death. Treatment is supportive and there is currently no licensed anti-dengue virus prophylactic or therapeutic compound. A single dengue vaccine, Sanofi Pasteur's Dengvaxia®, has been licensed in 20 countries but uptake has been poor. A safety signal in dengue seronegative vaccine recipients stimulated an international re-look at the vaccine performance profile, new World Health Organization recommendations for use, and controversy in the Philippines involving the government, regulatory agencies, Sanofi Pasteur, clinicians responsible for testing and administering the vaccine, and the parents of vaccinated children. In this review, we provide an overview of Dengvaxia's® development and discuss what has been learned about product performance since its licensure.

Keywords: Dengue vaccine; Dengvaxia®; efficacy; immunogenicity; safety.

PubMed Disclaimer

References

    1. Gubler DJ. Dengue, urbanization and globalization: The Unholy Trinity of the 21(st) century. Trop Med Health. 2011;39(4 Suppl):3–11. PubMed PMID: 22500131; PubMed Central PMCID: PMCPMC3317603. doi:10.2149/tmh.2011-S05. - DOI - PMC - PubMed
    1. Guzman MG, Gubler DJ, Izquierdo A, Martinez E, Halstead SB. Dengue infection. Nat Rev Dis Primers. 2016;2:16055 PubMed PMID: 27534439. doi:10.1038/nrdp.2016.55. - DOI - PubMed
    1. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, Hoen AG, Sankoh O, et al. The global distribution and burden of dengue. Nature. 2013;496(7446):504–07. PubMed PMID: 23563266; PubMed Central PMCID: PMCPMC3651993. doi:10.1038/nature12060. - DOI - PMC - PubMed
    1. Salje H, Cummings DAT, Rodriguez-Barraquer I, Katzelnick LC, Lessler J, Klungthong C, Thaisomboonsuk B, Nisalak A, Weg A, Ellison D, et al. Reconstruction of antibody dynamics and infection histories to evaluate dengue risk. Nature. 2018;557(7707):719–23. 10.1038/s41586-018-0157-4. PubMed PMID: 29795354. doi:10.1038/s41586-018-0157-4. - DOI - PMC - PubMed
    1. Katzelnick LC, Montoya M, Gresh L, Balmaseda A, Harris E. Neutralizing antibody titers against dengue virus correlate with protection from symptomatic infection in a longitudinal cohort. Proc Natl Acad Sci U S A. 2016;113(3):728–33. PubMed PMID: 26729879; PubMed Central PMCID: PMCPMC4725482. doi:10.1073/pnas.1522136113. - DOI - PMC - PubMed